Kymera Therapeutics, Inc.
KYMRNASDAQHealthcare● Active
$74.39
+$0.26(+0.35%)
Market Cap$6.1B
P/E Ratio—
52W High$103
52W Low$36.65
Kymera Therapeutics, Inc. (KYMR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KYMR · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $39.20M | $47.07M | $78.59M | $46.83M | $72.83M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $39.20M | $47.07M | $78.59M | $46.83M | $72.83M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $316.60M | $240.25M | $189.08M | $164.25M | $137.02M |
| G&A Expenses | $68.20M | $63.53M | $55.04M | $43.83M | $36.34M |
| Total Operating Expenses | $388.60M | $308.71M | $244.12M | $208.08M | $173.36M |
| Operating Income | ($349.40M) | ($261.63M) | ($165.53M) | ($161.26M) | ($100.53M) |
| Operating Margin %(computed) | -891.33% | -555.82% | -210.62% | -344.37% | -138.03% |
| Interest Income | $38.03M | $38.03M | $18.76M | $6.62M | $0.49M |
| Interest Expense | $0.25M | $0.25M | $0.20M | $0.18M | $0.17M |
| Income Before Tax | ($311.62M) | ($223.86M) | ($146.96M) | ($154.81M) | ($100.22M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($311.40M) | ($223.86M) | ($146.96M) | ($154.81M) | ($100.22M) |
| Net Margin %(computed) | -794.39% | -475.57% | -186.99% | -330.60% | -137.60% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 |
| Wtd Avg Shares | 84.39M | 75.04M | 58.37M | 53.93M | 47.99M |
| EBITDA | ($303.06M) | ($216.24M) | ($143.20M) | ($151.66M) | ($97.64M) |
| EBITDA Margin %(computed) | -773.11% | -459.37% | -182.21% | -323.87% | -134.07% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Kymera Therapeutics, Inc. data
About Kymera Therapeutics, Inc. (KYMR) Income Statement
Kymera Therapeutics, Inc. (KYMR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KYMR reported revenue of $0.04B, gross profit of $0.04B (gross margin 100.00%), and net income of ($0.31B) — a net profit margin of -794.39%.
Frequently asked questions
KYMR · 4 questionsKymera Therapeutics, Inc. (KYMR) reported revenue of $0.04B for 2025, down 16.7% year-over-year.
KYMR revenueKYMR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08